EFNB2

Across TCGA pan-cancer cohorts, EFNB2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EFNB2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EFNB2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFNB2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LUAD, LSCC, and UCEC are the cancer types where EFNB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.813	0.990	.012	7	view →
LSCC	DFS	Median	II,III,IV	0.860	0.692	.041	7	view →
UCEC	OS	Median	All	0.860	0.980	.019	6	view →
CCRCC	OS	Quartile	III,IV	0.954	0.585	.021	5	view →
PDAC	OS	Median	II,III,IV	0.899	0.785	.042	4	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	3	view →
GBM	OS	Tertile	All	0.974	0.792	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EFNB2–LUAD (DFS)

Open the LUAD breakdown →